FDA Shelving Broad Warnings on Hormone Replacement Therapies
- November 14, 2025
The Food and Drug Administration (FDA) is working with drug manufacturers to remove broad “black box” warnings from hormone replacement therapy (HRT) in a bid to improve uptake of the treatment for menopause symptoms like hot flashes, night sweats, and bone loss, the agency announced November 10.
ARTICLE TAGS
You must be logged in to access this content.